{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:22:08Z","timestamp":1783635728112,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.nmd.2026.106441","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:15:33Z","timestamp":1777011333000},"page":"106441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Sensory neuronopathy secondary to gene therapy with AT845 for Pompe disease"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5016-6794","authenticated-orcid":false,"given":"Laura","family":"Pena-Guzman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Bolano-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinta","family":"Lleix\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Querol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Trainor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Suetterlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2941-7988","authenticated-orcid":false,"given":"Jordi","family":"D\u00edaz-Manera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2026.106441_bib0001","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.nmd.2026.106441_bib0002","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.nmd.2026.106441_bib0003","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.nmd.2023.09.008","article-title":"261st ENMC international workshop: management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands","volume":"33","author":"Servais","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2026.106441_bib0004","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 Suppression with adeno-associated virus and MicroRNA in familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2026.106441_bib0005","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5413","article-title":"Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2","volume":"12","author":"Sondhi","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.nmd.2026.106441_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.880","article-title":"Rapid neurophysiological screening for sensory ganglionopathy: a novel approach","volume":"7","author":"Zis","year":"2017","journal-title":"Brain Behav"},{"key":"10.1016\/j.nmd.2026.106441_bib0007","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209725","article-title":"Antibodies in autoimmune neuropathies: what to test, how to test, why to test","volume":"103","author":"Pascual-Goni","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2026.106441_bib0008","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: a current review","volume":"81","author":"Staff","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2026.106441_bib0009","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1212\/WNL.42.7.1367","article-title":"Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity","volume":"42","author":"Berger","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2026.106441_bib0010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1474-4422(05)70096-X","article-title":"Sensory neuron diseases","volume":"4","author":"Sghirlanzoni","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2026.106441_bib0011","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-2008-1040868","article-title":"Neuropathies associated with malignancy","volume":"18","author":"Amato","year":"1998","journal-title":"Semin Neurol"},{"key":"10.1016\/j.nmd.2026.106441_bib0012","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ncl.2025.05.004","article-title":"Pattern recognition approach to neuropathy and neuronopathy","volume":"43","author":"Barohn","year":"2025","journal-title":"Neurol Clin"},{"key":"10.1016\/j.nmd.2026.106441_bib0013","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9188","article-title":"MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates","volume":"12","author":"Hordeaux","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.nmd.2026.106441_bib0014","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2026.106441_bib0015","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1089\/hum.2021.255","article-title":"Single-dose intrathecal dorsal root ganglia toxicity of onasemnogene abeparvovec in Cynomolgus monkeys","volume":"33","author":"Tukov","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.nmd.2026.106441_bib0016","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/d41573-021-00164-x","article-title":"Gene therapy community grapples with toxicity issues, as pipeline matures","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nmd.2026.106441_bib0017","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-025-04103-w","article-title":"Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial","volume":"32","author":"Proud","year":"2026","journal-title":"Nat Med"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626001094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626001094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:10:38Z","timestamp":1783635038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896626001094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":17,"alternative-id":["S0960896626001094"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2026.106441","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sensory neuronopathy secondary to gene therapy with AT845 for Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2026.106441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106441"}}